Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New...(ration System; the possibility that due ...),Health

Date:5/21/2008

ration System; the possibility that due to the nature of the research being performed, other laboratories may not find the use of ProteoSolve-LRS and PCT to be as advantageous as reported by Dr. Ivanov and by Dr. Pevsner and his colleagues; due to scientific and medical challenges, the possibility that the data generated by Dr. Ivanov, and by Dr. Pevsner and his colleagues, or that may be generated by other researchers in the future, may not be beneficial in the development of new therapeutics and diagnostics for breast and colon cancer, IVF, stroke, or other procedures and diseases; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.

Edward H. Myles, Senior Vice President (508) 230-1828 (T)

of Finance & CFO

'/>"/>

SOURCE Pressure BioSciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Seven-Year Neck Pain Study Sheds Light on Best Care
2. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
3. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
4. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
5. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
6. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
7. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
8. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
11. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting